Background. The Japan Thyroid Association recently published guidelines for clinical practice for the management of thyroid nodules, which include a diagnostic system for reporting thyroid fine needle aspiration cytology. It is characterized by the subclassification of follicular neoplasms, which is different from other internationally accepted reporting systems. Materials and Methods. This study examined observer variability in the subclassification of follicular neoplasms among 4 reviewers using Papanicolaou-stained smear samples from 20 surgically treated patients with indeterminate cytology. Results. The favor malignant subcategory had high predictive value of malignancy (risk of malignancy: 60-75%) and good agreement among the 4 reviewers (κ = 0.7714). Conclusion. These results clearly confirmed that the risk stratification of follicular neoplasms, which was adapted from cytology practice of high-volume thyroid centers in Japan, can provide clinically helpful information to estimate the risk of malignancy and to triage patients for surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334867 | PMC |
| http://dx.doi.org/10.1155/2015/938305 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extrafollicular Adenomatoid Odontogenic Tumors: A Series of Five Rare Cases with an Insight into Its Clinicopathological Aspects.
Contemp Clin Dent
December 2024
Department of Oral Pathology, Dr. R Ahmed Dental College, Kolkata, West Bengal, India.
Adenomatoid odontogenic tumors (AOT), first described by Steensland in 1905, are benign, slowly enlarging, nonaggressive, odontogenic epithelial neoplasms comprising 3%-7% of all odontogenic tumors. They tend to originate from the dental lamina remnants or the reduced enamel epithelium. Mutation at codon 12 of KRAS oncogene (Kirsten rat sarcoma viral oncogene homolog) plays a pivotal role in the pathogenesis.
View Article and Find Full Text PDFEnhancing oocyte competence in patients with polycystic ovarian syndrome: A microfluidic study on the effects of follicular fluid meiosis-activating sterol in in vitro oocyte maturation.
J Obstet Gynaecol Res
January 2025
Reproductive Sciences and Technology Research Center, Department of Anatomy, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Objective: To evaluate the efficacy of a microfluidic culture system supplemented with follicular fluid meiosis-activating sterol (FF-MAS) on the maturation of immature oocytes in patients with polycystic ovarian syndrome (PCOS).
Methods: A total of 438 germinal vesicle oocytes from 163 PCOS patients were included. Oocytes were divided into five groups: (1) cultured in static drops without FF-MAS, (2) cultured in static drops with FF-MAS, (3) cultured in a microfluidic device without FF-MAS, (4) cultured in a microfluidic device with FF-MAS for the first 2 h, and (5) cultured in a microfluidic device with FF-MAS for 24 h.
Study on the effects of Mogroside V in inhibiting NLRP3-mediated granulosa cell pyroptosis and insulin resistance to improve PCOS.
J Ovarian Res
January 2025
The First Affiliated Hospital, Gynecology&Obstetrics and Reproductive Medical Center, School of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.
Objective: Polycystic Ovary Syndrome (PCOS) is a prevalent endocrinopathy in reproductive-aged women, contributing to 75% of infertility cases due to ovulatory dysfunction. The condition poses significant health and psychological challenges, making the study of its pathogenesis and treatment a research priority. This study investigates the effects of Mogroside V (MV) on PCOS, focusing on its anti-inflammatory and anti-insulin resistance properties.
View Article and Find Full Text PDFA case series of ultrasound and pathological assessment of follicular thyroid tumors: Addressing indeterminate malignancy.
Medicine (Baltimore)
January 2025
Department of Pathology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, China.
Rationale: Follicular tumors with uncertain malignant potential of the thyroid are a new classification of thyroid tumors in the World Health Organization (2017). Only a few cases of evaluating the value of ultrasound combined with pathological examination in diagnosing follicular tumors with uncertain malignant potential of the thyroid have been reported in recent decades.
Patient Concerns: A retrospective analysis was performed on 18 patients with follicular tumors with uncertain thyroid malignant potential who underwent preoperative ultrasonography and were confirmed by operation and pathology in our hospital from January 2019 to November 2024.
Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma.
Signal Transduct Target Ther
January 2025
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Immunomodulatory agent lenalidomide is effective in treating follicular lymphoma (FL). We conducted the first trial of immunotherapy rituximab plus lenalidomide in newly diagnosed FL in China (NCT03715309). One-hundred and fifteen patients were enrolled and treated with rituximab 375 mg/m intravenously on day 0 and lenalidomide 25 mg orally on day 1-10 for 6 cycles of induction treatment, as well as lenalidomide for 6 cycles and rituximab for 8 cycles of maintenance treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!